Skip to main content
Journal of the American Society of Nephrology : JASN logoLink to Journal of the American Society of Nephrology : JASN
. 2013 Dec 19;25(5):1028–1036. doi: 10.1681/ASN.2013060671

Cubilin Maintains Blood Levels of HDL and Albumin

Obaidullah Aseem *, Brian T Smith *, Marion A Cooley *, Brent A Wilkerson *, Kelley M Argraves *, Alan T Remaley , W Scott Argraves *,
PMCID: PMC4005305  PMID: 24357674

Abstract

Cubilin is an endocytic receptor highly expressed in renal proximal tubules, where it mediates uptake of albumin and filtered forms of apoA-I/HDL. Cubilin deficiency leads to urinary loss of albumin and apoA-I; however, the consequences of cubilin loss on the homeostasis of blood albumin and apoA-I/HDL have not been studied. Using mice heterozygous for cubilin gene deletion (cubilin HT mice), we show that cubilin haploinsufficiency leads to reduced renal proximal tubular uptake of albumin and apoA-I and significantly increased urinary loss of albumin and apoA-I. Moreover, cubilin HT mice displayed significantly decreased blood levels of albumin, apoA-I, and HDL. The levels of albumin and apoA-I protein or mRNA expressed in the liver, kidney, or intestine of cubilin HT mice did not change significantly. The clearance rate of small HDL3 particles (density>1.13 g/ml) from the blood increased significantly in cubilin HT mice. In contrast, the rate of clearance of larger HDL2 particles from the blood did not change significantly, indicating a decreased half-life for HDL particles capable of filtering through the glomerulus. On the basis of these findings, we conclude that cubilin deficiency reduces renal salvage and delivery back to the blood of albumin and apoA-I, which decreases blood levels of albumin and apoA-I/HDL. These findings raise the possibility that therapeutic increase of renal cubilin expression might reduce proteinuria and increase blood levels of albumin and HDL.


HDL and albumin are major blood components with links to cardiovascular disease.13 As such, understanding the metabolism and homeostatic regulatory mechanisms of these constituents may hold keys to new therapeutic approaches.

Cubilin is a multiligand receptor capable of mediating the endocytosis of albumin and HDL, as well as its major apolipoprotein component, apoA-I.46 However, the significance of cubilin to the homeostasis of HDL and albumin in the blood has not been studied. Cubilin and its coreceptor LDL-related protein-2 (megalin) are expressed by absorptive cells, including proximal tubule cells (PTCs).7 At present, cubilin- and megalin-mediated endocytic uptake represents the only established process by which PTCs reabsorb proteins from the glomerular filtrate.5,6,8,9 Genetic alterations that affect renal cubilin expression in humans, dogs, and mice result in urinary wastage of an array of macromolecules, including albumin and apoA-I.10,11

Although several studies demonstrate the role of cubilin in mediating renal uptake of apoA-I and albumin,5,10,11 the precise fate of these proteins following PTC uptake has been an open question. Although a general view is that ligand endocytosis by cubilin and megalin leads to lysosomal degradation of ligands, several lines of evidence indicate that cubilin-megalin–mediated uptake may also participate in a process by which certain ligands are targeted for transcytosis and delivery back to the blood. For example, in cultured renal PTCs, megalin mediates transcytosis of transcobalamin–B12 complex12 and retinol-binding protein in complex with retinol/vitamin A.13 Megalin also mediates transcytosis of thyroglobulin,14 Shh,15 and the megalin-cubilin binding protein, receptor-associated protein.16 Indirect evidence for cubilin playing a similar role in ligand transcytosis comes from findings showing that albumin is transcytosed back to circulation via the proximal tubule epithelium,1719 as well as the fact that cubilin-mediated uptake of intrinsic factor–B12 complex in the gut leads to its release into blood in the form of transcobalamin–B12.20

Whether or not renal cubilin-mediated uptake of apoA-I and albumin from the glomerular filtrate might be part of a salvage process that affects levels of these proteins in the blood is not known. Here, we sought to define the relationships between genetic cubilin deficiency and renal uptake/urinary loss of apoA-I and albumin, along with the extent to which cubilin deficiency influences blood levels of each constituent, as well as HDL.

Results

Cubilin Heterozygous Mice

Cubilin gene (Cubn) deletion mice were previously generated by Cubn exon 1–6 deletion and an EGFP cassette insertion (Cubn+/delexon1–6;EGFP).21 As previously shown,21 cubilin-null mice are embryonic lethal. However, Cubn+/delexon1–6;EGFP mice (Cubn heterozygous mice) develop without any obvious abnormalities and are physically similar to wild-type (WT) littermates. BUN, urinary creatinine excretion, and total urine output levels did not significantly differ between Cubn heterozygous and WT mice (data not shown). As shown in Figure 1, Cubn heterozygous mice had significantly reduced cubilin protein levels in the extracts of ileum and kidney cortex compared with WT mice. Cubilin coreceptor (megalin) levels in Cubn heterozygous mice kidneys were not significantly different compared with WT (Figure 1A).

Figure 1.

Figure 1.

Cubn+/delexon1–6;EGFP mice have reduced expression of cubilin protein in the kidney and intestine compared with WT mice. (A) Anticubilin, antimegalin, and antiactin immunoblot analysis of detergent extracts of kidney cortex from WT and Cubn+/delexon1–6;EGFP (HT) mice. (B) Anticubilin and anti-actin immunoblot analysis of detergent extracts of ileum from WT and Cubn+/delexon1–6;EGFP mice. (C and D) Densitometric analyses of the anticubilin immunoblots shown in A and B, respectively. Horizontal lines in C and D indicate median values for each data group. The findings are representative of at least three experiments.

Effect of Cubilin Deficiency on Blood HDL Levels

To determine the effect of cubilin deficiency on the blood levels of HDL, multiple approaches were applied to analyze plasma or serum from fasted mice. First, serum lipoprotein levels were analyzed by nuclear magnetic resonance.22 As shown in Figure 2, HDL-associated cholesterol (HDL-C) was significantly reduced by approximately 27% in serum from Cubn heterozygous mice compared with WT. Similarly, HDL particle concentration was also significantly reduced by about 29% in serum from Cubn heterozygous mice compared with WT mice. By contrast, VLDL and LDL particle concentrations in serum did not significantly different between Cubn heterozygous mice and WT mice. Next, pooled plasma samples were separated by fast protein liquid chromatography (FPLC) and the lipid content of each fraction analyzed. The fractions corresponding to the HDL peak (fractions 35–42) contained cholesterol, cholesterol ester, and phospholipids, which were significantly reduced by approximately 25% in the serum from Cubn heterozygous mice compared with WT mice (Figure 3). In contrast, these lipids did not significantly differ in the non-HDL fractions in serum from Cubn heterozygous mice compared with WT mice. Likewise, triglycerides, which are mostly associated with non-HDL lipoproteins, were not significantly different in serum from Cubn heterozygous mice compared with WT mice. Finally, plasma apoA-I concentration was analyzed by a two-antibody sandwich ELISA using purified apoA-I as standard. Congruent with the above approaches, apoA-I concentration in plasma from Cubn heterozygous mice decreased by about 30% compared with WT mice (Figure 4A).

Figure 2.

Figure 2.

Nuclear magnetic resonance analysis of serum lipoproteins shows reduced serum HDL levels in Cubn+/delexon1–6;EGFP mice. (A) VLDL. (B) LDL. (C) HDL particle concentration. (D) HDL-C measured in fasted serum samples from age-matched adult male Cubn+/delexon1–6;EGFP (HT) and WT mice. Horizontal lines in each panel indicate median values for each data group. P value calculations were based on Mann–Whitney U tests (n=9 WT, 8 HT).

Figure 3.

Figure 3.

FPLC gel filtration analysis of serum shows reduced serum HDL levels in Cubn+/delexon1–6;EGFP mice. (A) Cholesterol. (B) Cholesterol ester. (C) Phospholipids. (D) Triglyceride levels in fractions of pooled serum samples (6 WT and 6 HT) subjected to gel filtration using Superose 6 column chromatography. Serum samples were obtained from age-matched adult male Cubn+/delexon1–6;EGFP (HT) and WT mice after a 15-hour fast.

Figure 4.

Figure 4.

Cubn+/delexon1–6;EGFP mice have reduced plasma apoA-I and increased urinary apoA-I levels, which are inversely correlated. (A and B) Levels of apoA-I in plasma (A) and urine (B) samples obtained from age-matched 1-year-old male Cubn+/delexon1–6;EGFP (HT) and WT mice. Samples were analyzed by a two-antibody sandwich ELISA using purified apoA-I as standard. Horizontal lines in A and B indicate median values for each data group. P value calculations in A and B were based on Mann–Whitney U tests. (C) The inverse correlation of plasma apoA-I and urinary apoA-I levels from Cubn+/delexon1–6;EGFP (HT) (Spearman r=−0.70, P=0.02; linear regression R2=0.47, P=0.04) and WT mice (Spearman r=−0.78, P=0.003; linear regression R2=0.37, P=0.05).

Effect of Cubilin Deficiency on Urinary ApoA-I Loss

To determine the effect of cubilin deficiency on urine levels of apoA-I, urine samples were analyzed by the two-antibody sandwich ELISA using purified apoA-I as standard. As shown in Figure 4B, apoA-I levels were significantly increased by approximately 4.5-fold in the urine of Cubn heterozygous mice compared with WT mice. This urinary loss amounted to an average of 45.44 ng of apoA-I per day in the urine of Cubn heterozygous mice compared with 9.04 ng/d in the WT mice (average daily excretion, 0.5 mg of creatinine in 1 ml of urine). To determine whether or not there was a correlation between urinary apoA-I loss and decreased plasma apoA-I levels, urinary apoA-I concentrations were plotted against plasma apoA-I levels (Figure 4C). A significant inverse correlation was observed between urinary apoA-I and plasma apoA-I concentration in both Cubn heterozygous and WT groups (WT, Spearman r=−0.78, P=0.003; Cubn heterozygous (HT), Spearman r=−0.7, P=0.02).

Effect of Cubilin Deficiency on Blood Albumin Levels

To determine the effect of cubilin deficiency on blood levels of albumin, plasma samples from fasted mice were analyzed using a two-antibody sandwich ELISA. Plasma albumin was significantly reduced by approximately 17% in Cubn heterozygous mice compared with WT (Figure 5A). Because albumin constitutes a large portion of blood protein content,23 total plasma protein was also quantified using a bicinchoninic acid protein assay. As shown in Figure 5B, total plasma protein was significantly reduced by about 12% in Cubn heterozygous mice compared with WT mice.

Figure 5.

Figure 5.

Cubn+/delexon1–6;EGFP mice have reduced plasma albumin and increased urinary albumin levels. (A and C) Levels of albumin in plasma (A) and urine (C) samples obtained from age-matched 1-year-old male Cubn+/delexon1–6;EGFP (HT) and WT mice. Samples were analyzed by a two-antibody sandwich ELISA for albumin. (B) Plasma samples analyzed for total protein using a bicinchoninic acid protein assay. Horizontal lines in each panel indicate median values for each data group. P value calculations in each panel were based on Mann–Whitney U tests.

Effect of Cubilin Deficiency on Urinary Albumin Loss

To determine the effect of cubilin deficiency on urine levels of albumin, spot urine and 16-hour urine samples were analyzed using the two-antibody sandwich ELISA. Albumin levels were significantly increased by approximately 2.4-fold in the urine of Cubn heterozygous mice compared with WT mice (Figure 5C). This urinary loss amounted to a daily average of 232.83 μg of albumin in the urine of Cubn heterozygous mice compared with 96.84 μg/d in the WT. Urine volumes and creatinine levels at 16 and 24 hours were not significantly different between Cubn heterozygous and WT mice (data not shown).

Cubilin Deficiency Does Not Alter Intestinal or Renal ApoA-I/HDL and Albumin Biosynthesis

To determine whether cubilin deficiency affected apoA-I/HDL biosynthesis, quantitative PCR was used to measure tissue mRNA levels of apoA-I and Abca1, which catalyzes the rate-limiting step in the lipidation of apoA-I into nascent HDL particles.24 As shown in Figure 6, A and F, cubilin mRNA levels were significantly decreased by approximately 50% in the intestine and kidney of Cubn heterozygous mice compared with WT mice. However, there was no significant difference in apoA-I and Abca1 mRNA levels in the intestine, liver, or kidney of Cubn heterozygous mice compared with WT mice (Figure 6). Similarly, no significant difference was observed in albumin mRNA levels in the intestine or liver of Cubn heterozygous mice compared with WT mice (data not shown). ApoA-I and Abca1 immunoblot analysis of extracts of these tissues was also performed. Consistent with findings from the mRNA analyses, no significant differences were observed in apoA-I and Abca1 protein levels in the extracts of intestine or liver from Cubn heterozygous mice compared with WT mice (Supplemental Figure 1).

Figure 6.

Figure 6.

Cubilin haploinsufficiency does not affect ApoA-I and Abca1 mRNA expression in the intestine, liver, and kidney. qPCR analysis of Cubn (A and F), apoA-I (B, D, and G), and Abca1 (C, E, and H) transcript levels in mRNA extracted from intestine, liver, and kidney of age-matched Cubn+/delexon1–6;EGFP (HT) and WT mice. Horizontal line indicates median values for each data group. P value calculations in each panel were based on Mann–Whitney U tests.

Effect of Cubilin Deficiency on ApoA-I/HDL Fractional Clearance

The clearance from blood of intravenously injected human HDL fractions was measured in Cubn heterozygous and WT mice. At 48 and 72 hours after injection, levels of human HDL3 were significantly reduced (by about 50%) in Cubn heterozygous mice compared with WT mice (Figure 7A). The area under the curve for apoA-I/HDL plasma clearance in Cubn heterozygous mice was significantly reduced (by approximately 29%) compared with WT mice (Figure 7A). Similarly, the average half-life of these HDL particles was also reduced by about 28% in Cubn heterozygous mice compared with WT mice (half-life in WT mice, 15–18 hours; half-life in HT mice, 9–15 hours). These observations indicate that apoA-I/HDL fractional clearance is significantly increased in Cubn heterozygous mice compared with WT mice. As a control, the fractional clearance of the larger HDL2 fraction was also determined. Most of HDL2 should not be filtered through the glomerulus because of its larger size.25 As shown in Figure 7B, the plasma concentration of human HDL2 in WT mice was not significantly different compared with Cubn heterozygous mice at all time points. Furthermore, the area under the curve for HDL2 plasma clearance in WT mice was also not significantly different compared with Cubn heterozygous mice (Figure 7B).

Figure 7.

Figure 7.

Cubn+/delexon1–6;EGFP mice have increased fractional clearance of small HDL particles. (A) Fractional clearance of human HDL3 (d>1.13 g/ml) supplemented with 6% purified apoA-I infused into Cubn+/delexon1–6;EGFP (HT) (n=6) and WT (n=3) mice. Areas under the curves in A were statistically different (P=0.05). (B) Fractional clearance of human HDL2 (d=1.11–1.13 g/ml) infused into WT and HT mice (n=3 and 5, respectively). Analysis showed no statistically significant difference between the two data sets in B (i.e., area under the curves, P=0.11).

Effect of Cubilin Deficiency on ApoA-I Localization in Kidney Cortex

To determine the effect of cubilin deficiency on apoA-I uptake by proximal tubules, apoA-I localization was analyzed in the kidney cortex by immunofluorescence microscopy. Previously, we showed that cubilin expression is monoallelic.26 Thus, proximal tubules in the Cubn heterozygous mice stochastically express either the targeted Cubn allele (containing the EGFP cassette) or the WT cubilin allele. The enhanced green fluorescent protein (EGFP)–expressing proximal tubule cells are cubilin deficient, and their brush borders had significantly less bound albumin than proximal tubules with WT cubilin expression.26 Similarly, we show here that apoA-I localization in the brush border of EGFP-expressing cubilin-deficient proximal tubules in the Cubn heterozygous mouse kidney is greatly reduced (Figure 8). The level of apoA-I localization to proximal tubule brush borders was quantified by counting the number of proximal tubules with detectable apoA-I immunofluorescence in 109 images from four WT and five HT mice. The number of apoA-I–positive proximal tubules was significantly reduced, by 36%, in Cubn heterozygous mice compared with WT mice (Figure 8C).

Figure 8.

Figure 8.

Cubn+/delexon1–6;EGFP mouse renal proximal tubules show reduced apical levels of apoA-I. (A) Image of a WT mouse kidney section immunolabeled with anti–apoA-I (red) and anti-EGFP (green). Nuclei were stained with Draq5. (B) Cubn+/delexon1–6;EGFP kidney section labeled similarly to A. Note that very little or no apoA-I is present on the apical aspects of tubules expressing EGFP. (C) Graph showing the percentage of anti–apoA-I immunolabeling positive proximal tubules counted from 109 low-magnification fields from four WT and five HT mice. Horizontal line indicates median values for each data group. The P value was calculated using a Mann–Whitney U test.

Discussion

Here we show that cubilin haploinsufficiency in mice leads to decreased PTC uptake of both albumin and apoA-I and significantly increased loss of albumin and apoA-I in the urine. Importantly, our studies demonstrate that decreased PTC uptake of albumin and apoA-I causes significant decreases in plasma levels of albumin, apoA-I, and HDL particle concentration. This was supported by an inverse correlation between urinary loss of apoA-I and plasma apoA-I levels and analyses of HDL half-life and clearance rate from blood. Indeed, cubilin HT mice had significantly reduced blood half-life and increased blood clearance rate of small HDL particles. In contrast, there was not a significant difference in the clearance rate from blood of HDL2, larger particles that are not filtered through the glomerulus.27 On the basis of these findings, we inferred that the increased urinary loss of apoA-I/HDL would result in a continuous decline in blood HDL levels until it is counterbalanced by an increase in synthesis or decrease in degradation of apoA-I/HDL, resulting in a new homeostatic level of apoA-I/HDL that is lower than WT levels. We did not find a significant difference in apoA-I biosynthesis at the mRNA or protein level in cubilin HT mouse tissues compared with WT. Thus, a decrease in apoA-I/HDL degradation is likely to provide the counterbalance measure to allow blood apoA-I/HDL levels in cubilin HT to reach steady state.

Our conclusion that cubilin-mediated salvage of albumin is tied to blood albumin homeostasis is consistent with findings from other studies. In a study of doxorubicin-induced rat kidney injury, RNA interference–mediated silencing of renal cubilin expression not only led to increased albuminuria, but also resulted in reduced blood albumin levels.28 In studies of protein overload in mice, BSA overload caused urinary wastage of cubilin ligands and resulted in reduced serum albumin levels without any changes in glomerular function or ultrastructure.23,29

The data here, together with findings from other studies, point to a mechanism involving PTC cubilin-mediated uptake of apoA-I and albumin from the glomerular filtrate, leading to transcytosis of these ligands across the renal proximal tubule cells and delivery back into circulation. Support for such a mechanism comes from live renal imaging studies showing transcytosis of albumin in rat PTCs and other studies demonstrating the in vitro transcytosis of megalin ligands.12,13,1719,30 The underlying mechanisms by which cubilin-mediated uptake would lead to ligand transcytosis remains to be established. In a recent study, a significant reduction in plasma albumin levels and decreased half-life of albumin in the blood were observed in mice transplanted with kidneys deficient in neonatal Fc receptor (FcRn).19 FcRn is expressed by renal podocytes and PTCs and binds albumin under acidic conditions.3133 However, FcRn-deficient PTCs retained the capacity to bind albumin at their apical brush borders.19 This is consistent with other studies showing that FcRn is expressed within the cytoplasm and not at the plasma membrane.34 Together, these studies suggest that after cubilin-mediated endocytosis, albumin might then bind to FcRn in acidic vesicles and become routed for transcytosis.19,34 Therefore, at least in case of albumin, the transcytosis pathway might involve cooperation of cubilin and FcRn.

A role for renal cubilin-mediated salvage in maintaining HDL and albumin homeostasis could have implications for cardiovascular diseases (CVD). Clinical evidence indicates that HDL-C blood levels and serum albumin levels are inversely correlated with risk of coronary heart disease.1,2,3537 Emerging evidence indicates that this salvage pathway might be affected in human disease, with consequential effects on HDL and albumin homeostasis. For example, elevated urinary albumin excretion was associated with a doubling of risk of CVD and all-cause mortality in a study of elderly persons. This study also showed an inverse correlation between urinary levels of albumin and plasma levels of HDL-C.38 Similarly, patients with chronic renal failure have decreased plasma HDL concentration.39 Furthermore, a missense cubilin variant is associated with albuminuria in both the general population and individuals with diabetes.40

Decreased renal cubilin-mediated salvage may affect HDL homeostasis in diabetes. In mouse models of diabetes, levels of renal cubilin are decreased.41 Although renal cubilin levels have not been directly analyzed in diabetic patients, one study of microalbuminuric patients with type 1 diabetes reported aberrant shedding of cubilin in urine along with cubilin ligands, albumin, and apoA-I.42 Other studies demonstrate that diabetic patients have lower blood HDL levels.43 Furthermore, a study of normoalbuminuric patients with type 1 diabetes and normal glomerular function reported a correlation between lower levels of total HDL-C and smaller HDL3-C with albuminuria, but not larger HDL2-C.44 Similarly, HDL size distribution has shifted toward large particles in patients with proteinuria.45 However, further work is required to analyze cubilin expression in these patient populations and determine whether a causal link exists between any changes in cubilin expression and altered HDL levels. Demonstrating such a link would emphasize the need to upregulate the renal cubilin-mediated salvage pathway to prevent CVD in these patient populations.

Concise Methods

Animals

All studies involved the use of 2- to 12-month-old male mice: either cubilin heterozygous with an EGFP cassette insertion in a site in which cubilin exons 1–6 were deleted (Cubn+/delexon1–6;EGFP)21 or age- and sex-matched WT littermates on a mixed 129Sv/C57BL/6 genetic background. Mice were housed in a Medical University of South Carolina (MUSC) animal care facility, and mouse experiments were conducted with approval from the MUSC Institutional Animal Care and Use Committee with adherence to the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals. The mean body weight was 32.84 g for WT mice and 33.07 g for cubilin heterozygous mice. Both WT and Cubn heterozygous mice were fed Harland Teklad Global 2918 rodent chow during this study. Genotypes of progeny were determined by PCR performed with tail-clip genomic DNA using a three-primer set: cubilin sense strand primer, 5′-AGCCACGCTTATACTTACTGGTG-3′ (residues 10413310–10413332 in NT_039202.7); cubilin antisense strand primer, 5′- TGACCCCTCACAAGTTGAACAG-3′ (residues 10413656–10413635 in NT_039202.7); and EGFP antisense strand primer, 5′- GGTCTTGTAGTTGCCGTCGT-3′ (residues 1281–1262 in GU045599.1). Cycling parameters for PCR amplification were 98°C for 5 minutes and then 40 cycles of 98°C for 0.5 minute, 55°C for 1 minute and 72°C for 1 minute. For WT animals, the expected size of the amplicon is about 350, whereas amplicons of about 350 and 520 bp are produced from Cubn heterozygous mice.

Immunoblot Analysis

Segments of small intestine, liver, and kidney cortex were homogenized in 1% Triton X-100, 0.5% Tween 20, 0.5 M NaCl, and 50 mM Hepes, pH 7.5, containing a protease inhibitor cocktail (Complete-mini, EDTA-free; Roche, Germany) using a Polytron-aggregate (Brinkmann Instruments, Switzerland). Extracts were clarified by centrifugation at 14,000g for 30 minutes at 4°C. Protein concentration in extracts was quantified using Pierce BCA Protein Assay Kit (Rockford, IL). Equal amounts of protein from the extracts were loaded onto NuPAGE 4%–12% polyacrylamide gradient, Bis-Tris gels in the presence of SDS (no reducing agent). After electrophoresis, the proteins were transferred onto polyvinylidene fluoride membranes, which were blocked with 5% nonfat milk in Tris-buffered saline and probed with antibodies diluted in Tris-buffered saline containing 0.5% Tween-20, 5% nonfat milk. Antibodies used in immunoblotting included goat anti-cubilin A20 (Santa Cruz Biotechnology), rabbit anti–smooth muscle actin (Abcam, Cambridge, MA), goat anti–apoA-I (ab7614; Abcam), and rabbit anti-ABCA1 (NB400–105; Novus Biologic, Littleton, CO). Rabbit anti-porcine megalin (rb6286) was described previously.46 Chemiluminescent detection of bound antibodies was achieved using the Pierce ECL Western blotting substrate.

Immunohistochemistry

Mouse kidneys were fixed initially by perfusion fixation followed by immersion of kidney segments in 4% paraformaldehyde PBS for 12 hours. Kidney segments were then embedded in paraffin and sectioned at 6-μm thickness. Tissue sections were incubated with rabbit polyclonal anti-EGFP IgG (Abcam) and goat anti–apoA-I (ab7614; Abcam). Tissue sections were incubated with donkey anti-goat and donkey anti-rabbit Alexa Fluor (488 or 568) conjugates (Invitrogen, Carlsbad, CA). Nuclei were stained using Draq5 (Cell Signaling Technology, Danvers, MA). Immunolabeled sections were analyzed using a Leica SP5 confocal microscope (Leica Microsystems, Inc., Exton, PA).

Urine Analysis

Urine was collected from male mice over a 5-day period. Mice were individually placed in diuresis cages from 5 PM to 8 AM with 10% sucrose, but no food. From 8 AM to 5 PM, the mice were returned to regular cages and given food and water. This cycle was repeated for 5 days. Spot urine samples were collected from mice on regular chow diet and pooled from 5 consecutive days. Urinary creatinine levels were measured by ELISA using a Creatinine Companion kit (Exocell, Inc., Philadelphia, PA). Albumin levels in urine (diluted 1:500 in PBS) were measured by ELISA using the Mouse Albumin ELISA Quantitation Set (Bethyl Laboratories, Inc., Montgomery, TX). ApoA-I levels in urine (diluted 1:20 in PBS) were measured by a two-antibody sandwich ELISA using goat anti-mouse apoA-I (ab7614) and rabbit anti-mouse apoA-I (ab20453; Abcam) and purified apoA-I as a standard (Calbiochem, Darmstadt, Germany).

Blood ApoA-I and Albumin Analysis

Blood from mice fasted for 6 hours was drawn by retro-orbital bleeding using heparinized micro-pipettes (Drummond Scientific Co., Broomall, PA). Drawn blood was kept on ice for approximately 1 hour, then subjected to centrifugation (2000g) and the plasma supernatant collected. ApoA-I levels in plasma (diluted 1:20,000 in PBS) were determined by a two-antibody sandwich ELISA (Abcam). Albumin levels in plasma (diluted 1:400,000 in PBS) were determined by a two-antibody sandwich ELISA (Bethyl Laboratories).

FPLC

FPLC separation of serum lipoproteins from pooled plasma samples (6 WT and 6 heterozygous mice) was achieved by gel filtration using two Superose 6HR 10/30 columns (Amersham Pharmacia Biotech, Piscataway, NJ) in series as previously described.47 Cholesterol, cholesterol ester, phospholipid, and triglyceride levels in each fraction were measured using enzymatic or immunoturbidimetric kits from Sigma-Aldrich (St. Louis, MO) and Wako Chemicals (Richmond, VA).

Analysis of Blood Lipoprotein Levels by Nuclear Magnetic Resonance

Quantitative analysis of serum lipoprotein levels from WT mice and heterozygotes (from fasted males) was performed by LipoScience, Inc. (Raleigh, NC) using nuclear magnetic resonance spectroscopy as described.22

Quantitative PCR

RNA from ileum, liver, and kidney cortex was isolated using RNA Stat-60 (Tel-test, Inc., Friendswood, TX), and quality was assessed on an Agilent Bioanalyzer. cDNA was prepared using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) according to manufacturer instructions. Quantitative PCR (qPCR) was performed using iQ SYBR Green Supermix (Quanta BioSciences, Inc., Gaithersburg, MD) reagents and a C1000 Thermal Cycler (Bio-Rad). The following qPCR primers were used: Cubilin sense, 5′-ATTTTCTCTGGGGTTTTGTTAC-3′ and Cubilin antisense, 5′-TAAGTTTCCCTCCTCCGTAG-3′ (NM_001081084.2); ApoA-I sense, 5′- AAGCCAGACCTGCGCTGGAG-3′ and ApoA-I antisense, 5′-AAAGCCAATGCGGGGGTGGG-3′; Abca1 sense, 5′-CGTTTCCGGGAAGTGTCCTA-3′ and Abca1 antisense, 5′-CTAGAGATGACAAGGAGGATGGA-3′; and Albumin sense, 5′- AGCCCAAGGCTACAGCGGAG-3′ (NM_013454.3)48 and Albumin antisense, 5′- GGGTAGCCTGAGAAGGTTGTGGT-3′ (NM_009654.2). Genes used for qPCR standardization included: β-actin sense, 5′-CGGGACCTGACAGACTACCTC-3′ and β-actin antisense, 5′-AACCGCTCGTTGCCAATA-3′ (NM_007393.3); Hprt1 sense, 5′- ATCATTATGCCGAGGATTTGGA-3′ and Hprt1 anti-sense, 5′-CACACAGAGGGCCACAATGT-3′ (NM_013556); and Rn18s sense, 5′- CGCCGCTAGAGGTGAAATTCT-3′ and Rn18s antisense 5′-CGAACCTCCGACTTTCGTTCT-3′ (NR_003278.2).

Preparation of Human Plasma HDL Subfractions

Human plasma HDL2 (d=1.11–1.13 g/ml) and HDL3 (d=1.13–1.25 g/ml) were isolated by density gradient ultracentrifugation as previously described.49 Total protein and apoA-I concentration was determined using Pierce BCA Protein Assay Kit and apoA-I ELISA as described above.

Human HDL Fractional Clearance in Mice

The clearance of HDL subfractions was measured in male mice following tail vein injection with HDL2 (approximately 15 μg/g body weight) or HDL3 supplemented with 6% purified apoA-I (Calbiochem) (approximately 40 μg/g).50 After the tail vein injection, blood samples were collected at 10 minutes by retro-orbital and subsequently by tail vein bleeding at 1, 3, 6, 12, 24, 48, and 72 hours. Human HDL subfraction concentrations in mouse plasma were determined by a two-antibody ELISA using rabbit anti–apoA-I (NB110–55465; Novus Biologic) and sheep anti–apoA-I (NB600–1538). The antibodies used in this ELISA are specific to human apoA-I and display no cross-reactivity to mouse apoA-I. Standard curves for these assays were generated using purified apoA-I (Calbiochem) diluted in 5% mouse plasma. The concentration of human HDL measured for each time point was normalized to the concentration measured at 10 minutes for each mouse and average values plotted on a log scale.

Statistical Analyses

Comparisons between WT and heterozygous mice were performed with GraphPad Prism (GraphPad Software, La Jolla, CA) using the Mann–Whitney U test. Horizontal lines depict median values.

Disclosures

None.

Acknowledgments

We especially thank Marloes M.A. Hensels for the superb technical assistance she provided for this study.

This work was supported by National Institutes of Health grants HL061873 (W.S.A.) and HL094883 (K.M.A.). O.A. was supported by a predoctoral fellowship from the American Heart Association (10PRE3870038). B.A.W. was supported by a predoctoral fellowship from the American Heart Association (10PRE3910006).

Footnotes

Published online ahead of print. Publication date available at www.jasn.org.

References

  • 1.Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707–714, 1977 [DOI] [PubMed] [Google Scholar]
  • 2.Kuller LH, Eichner JE, Orchard TJ, Grandits GA, McCallum L, Tracy RP: The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. Am J Epidemiol 134: 1266–1277, 1991 [DOI] [PubMed] [Google Scholar]
  • 3.Schalk BW, Visser M, Bremmer MA, Penninx BW, Bouter LM, Deeg DJ: Change of serum albumin and risk of cardiovascular disease and all-cause mortality: Longitudinal Aging Study Amsterdam. Am J Epidemiol 164: 969–977, 2006 [DOI] [PubMed] [Google Scholar]
  • 4.Hammad SM, Barth JL, Knaak C, Argraves WS: Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem 275: 12003–12008, 2000 [DOI] [PubMed] [Google Scholar]
  • 5.Kozyraki R, Fyfe J, Kristiansen M, Gerdes C, Jacobsen C, Cui S, Christensen EI, Aminoff M, de la Chapelle A, Krahe R, Verroust PJ, Moestrup SK: The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 5: 656–661, 1999 [DOI] [PubMed] [Google Scholar]
  • 6.Birn H, Fyfe JC, Jacobsen C, Mounier F, Verroust PJ, Orskov H, Willnow TE, Moestrup SK, Christensen EI: Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 105: 1353–1361, 2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Barth JL, Argraves WS: Cubilin and megalin: Partners in lipoprotein and vitamin metabolism. Trends Cardiovasc Med 11: 26–31, 2001 [DOI] [PubMed] [Google Scholar]
  • 8.Christensen EI, Verroust PJ, Nielsen R: Receptor-mediated endocytosis in renal proximal tubule. Pflugers Arch 458: 1039–1048, 2009 [DOI] [PubMed] [Google Scholar]
  • 9.Nielsen R, Christensen EI: Proteinuria and events beyond the slit. Pediatr Nephrol 25: 813–822, 2010 [DOI] [PubMed] [Google Scholar]
  • 10.Storm T, Emma F, Verroust PJ, Hertz JM, Nielsen R, Christensen EI: A patient with cubilin deficiency. N Engl J Med 364: 89–91, 2011 [DOI] [PubMed] [Google Scholar]
  • 11.Amsellem S, Gburek J, Hamard G, Nielsen R, Willnow TE, Devuyst O, Nexo E, Verroust PJ, Christensen EI, Kozyraki R: Cubilin is essential for albumin reabsorption in the renal proximal tubule. J Am Soc Nephrol 21: 1859–1867, 2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Nielsen R, Sørensen BS, Birn H, Christensen EI, Nexø E: Transcellular transport of vitamin B(12) in LLC-PK1 renal proximal tubule cells. J Am Soc Nephrol 12: 1099–1106, 2001 [DOI] [PubMed] [Google Scholar]
  • 13.Marinó M, Andrews D, Brown D, McCluskey RT: Transcytosis of retinol-binding protein across renal proximal tubule cells after megalin (gp 330)-mediated endocytosis. J Am Soc Nephrol 12: 637–648, 2001 [DOI] [PubMed] [Google Scholar]
  • 14.Marinò M, Zheng G, Chiovato L, Pinchera A, Brown D, Andrews D, McCluskey RT: Role of megalin (gp330) in transcytosis of thyroglobulin by thyroid cells. A novel function in the control of thyroid hormone release. J Biol Chem 275: 7125–7137, 2000 [DOI] [PubMed] [Google Scholar]
  • 15.Morales CR, Zeng J, El Alfy M, Barth JL, Chintalapudi MR, McCarthy RA, Incardona JP, Argraves WS: Epithelial trafficking of Sonic hedgehog by megalin. J Histochem Cytochem 54: 1115–1127, 2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Pan W, Kastin AJ, Zankel TC, van Kerkhof P, Terasaki T, Bu G: Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J Cell Sci 117: 5071–5078, 2004 [DOI] [PubMed] [Google Scholar]
  • 17.Sandoval RM, Wagner MC, Patel M, Campos-Bilderback SB, Rhodes GJ, Wang E, Wean SE, Clendenon SS, Molitoris BA: Multiple factors influence glomerular albumin permeability in rats. J Am Soc Nephrol 23: 447–457, 2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Russo LM, Sandoval RM, McKee M, Osicka TM, Collins AB, Brown D, Molitoris BA, Comper WD: The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: Retrieval is disrupted in nephrotic states. Kidney Int 71: 504–513, 2007 [DOI] [PubMed] [Google Scholar]
  • 19.Sarav M, Wang Y, Hack BK, Chang A, Jensen M, Bao L, Quigg RJ: Renal FcRn reclaims albumin but facilitates elimination of IgG. J Am Soc Nephrol 20: 1941–1952, 2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Seetharam B, Christensen EI, Moestrup SK, Hammond TG, Verroust PJ: Identification of rat yolk sac target protein of teratogenic antibodies, gp280, as intrinsic factor-cobalamin receptor. J Clin Invest 99: 2317–2322, 1997 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Smith BT, Mussell JC, Fleming PA, Barth JL, Spyropoulos DD, Cooley MA, Drake CJ, Argraves WS: Targeted disruption of cubilin reveals essential developmental roles in the structure and function of endoderm and in somite formation. BMC Dev Biol 6: 30, 2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hammad SM, Powell-Braxton L, Otvos JD, Eldridge L, Won W, Lyons TJ: Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. Metabolism 52: 916–921, 2003 [DOI] [PubMed] [Google Scholar]
  • 23.Ishola DA, Jr, van der Giezen DM, Hahnel B, Goldschmeding R, Kriz W, Koomans HA, Joles JA: In mice, proteinuria and renal inflammatory responses to albumin overload are strain-dependent. Nephrol Dial Transplant 21: 591–597, 2006 [DOI] [PubMed] [Google Scholar]
  • 24.Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR: Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 116: 1052–1062, 2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Webb NR, Cai L, Ziemba KS, Yu J, Kindy MS, van der Westhuyzen DR, de Beer FC: The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake. J Lipid Res 43: 1890–1898, 2002 [DOI] [PubMed] [Google Scholar]
  • 26.Aseem O, Barth JL, Klatt SC, Smith BT, Argraves WS: Cubilin expression is monoallelic and epigenetically augmented via PPARs. BMC Genomics 14: 405, 2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rader DJ: Molecular regulation of HDL metabolism and function: Implications for novel therapies. J Clin Invest 116: 3090–3100, 2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Liu J, Li K, He Y, Zhang J, Wang H, Yang J, Zhan J, Liang H: Anticubilin antisense RNA ameliorates adriamycin-induced tubulointerstitial injury in experimental rats. Am J Med Sci 342: 494–502, 2011 [DOI] [PubMed] [Google Scholar]
  • 29.Lee D, Gleich K, Fraser SA, Katerelos M, Mount PF, Power DA: Limited capacity of proximal tubular proteolysis in mice with proteinuria. Am J Physiol Renal Physiol 304: F1009–F1019, 2013 [DOI] [PubMed] [Google Scholar]
  • 30.Marinò M, McCluskey RT: Megalin-mediated transcytosis of thyroglobulin by thyroid cells is a calmodulin-dependent process. Thyroid 10: 461–469, 2000 [PubMed] [Google Scholar]
  • 31.Haymann JP, Levraud JP, Bouet S, Kappes V, Hagège J, Nguyen G, Xu Y, Rondeau E, Sraer JD: Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 11: 632–639, 2000 [DOI] [PubMed] [Google Scholar]
  • 32.Simister NE, Rees AR: Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol 15: 733–738, 1985 [DOI] [PubMed] [Google Scholar]
  • 33.Rodewald R: pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 71: 666–669, 1976 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Nagai J, Sato K, Yumoto R, Takano M: Megalin/cubilin-mediated uptake of FITC-labeled IgG by OK kidney epithelial cells. Drug Metab Pharmacokinet 26: 474–485, 2011 [DOI] [PubMed] [Google Scholar]
  • 35.Assmann G, Schulte H, von Eckardstein A, Huang Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124[Suppl]: S11–S20, 1996 [DOI] [PubMed] [Google Scholar]
  • 36.Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W, Atherosclerosis Risk in Communities Study Group : Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104: 1108–1113, 2001 [DOI] [PubMed] [Google Scholar]
  • 37.Linsel-Nitschke P, Tall AR: HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4: 193–205, 2005 [DOI] [PubMed] [Google Scholar]
  • 38.Cao JJ, Biggs ML, Barzilay J, Konen J, Psaty BM, Kuller L, Bleyer AJ, Olson J, Wexler J, Summerson J, Cushman M: Cardiovascular and mortality risk prediction and stratification using urinary albumin excretion in older adults ages 68-102: The Cardiovascular Health Study. Atherosclerosis 197: 806–813, 2008 [DOI] [PubMed] [Google Scholar]
  • 39.Kastarinen H, Hörkkö S, Kauma H, Karjalainen A, Savolainen MJ, Kesäniemi YA: Low-density lipoprotein clearance in patients with chronic renal failure. Nephrol Dial Transplant 24: 2131–2135, 2009 [DOI] [PubMed] [Google Scholar]
  • 40.Böger CA, Chen MH, Tin A, Olden M, Köttgen A, de Boer IH, Fuchsberger C, O’Seaghdha CM, Pattaro C, Teumer A, Liu CT, Glazer NL, Li M, O’Connell JR, Tanaka T, Peralta CA, Kutalik Z, Luan J, Zhao JH, Hwang SJ, Akylbekova E, Kramer H, van der Harst P, Smith AV, Lohman K, de Andrade M, Hayward C, Kollerits B, Tönjes A, Aspelund T, Ingelsson E, Eiriksdottir G, Launer LJ, Harris TB, Shuldiner AR, Mitchell BD, Arking DE, Franceschini N, Boerwinkle E, Egan J, Hernandez D, Reilly M, Townsend RR, Lumley T, Siscovick DS, Psaty BM, Kestenbaum B, Haritunians T, Bergmann S, Vollenweider P, Waeber G, Mooser V, Waterworth D, Johnson AD, Florez JC, Meigs JB, Lu X, Turner ST, Atkinson EJ, Leak TS, Aasarød K, Skorpen F, Syvänen AC, Illig T, Baumert J, Koenig W, Krämer BK, Devuyst O, Mychaleckyj JC, Minelli C, Bakker SJ, Kedenko L, Paulweber B, Coassin S, Endlich K, Kroemer HK, Biffar R, Stracke S, Völzke H, Stumvoll M, Mägi R, Campbell H, Vitart V, Hastie ND, Gudnason V, Kardia SL, Liu Y, Polasek O, Curhan G, Kronenberg F, Prokopenko I, Rudan I, Arnlöv J, Hallan S, Navis G, Parsa A, Ferrucci L, Coresh J, Shlipak MG, Bull SB, Paterson NJ, Wichmann HE, Wareham NJ, Loos RJ, Rotter JI, Pramstaller PP, Cupples LA, Beckmann JS, Yang Q, Heid IM, Rettig R, Dreisbach AW, Bochud M, Fox CS, Kao WH, CKDGen Consortium : CUBN is a gene locus for albuminuria. J Am Soc Nephrol 22: 555–570, 2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Zhou L, Liu F, Huang XR, Liu F, Chen H, Chung AC, Shi J, Wei L, Lan HY, Fu P: Amelioration of albuminuria in ROCK1 knockout mice with streptozotocin-induced diabetic kidney disease. Am J Nephrol 34: 468–475, 2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Thrailkill KM, Nimmo T, Bunn RC, Cockrell GE, Moreau CS, Mackintosh S, Edmondson RD, Fowlkes JL: Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilin. Diabetes Care 32: 1266–1268, 2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP: Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: The case for residual risk reduction after statin treatment. Open Cardiovasc Med J 5: 24–34, 2011 [DOI] [PMC free article] [PubMed]
  • 44.Bulum T, Kolaric B, Duvnjak L: Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric type 1 diabetic patients. J Endocrinol Invest 36: 574–578, 2013 [DOI] [PubMed] [Google Scholar]
  • 45.Soto-Miranda E, Carreón-Torres E, Lorenzo K, Bazán-Salinas B, García-Sánchez C, Franco M, Posadas-Romero C, Fragoso JM, López-Olmos V, Madero M, Rodriguez-Pérez JM, Vargas-Alarcón G, Pérez-Méndez O: Shift of high-density lipoprotein size distribution toward large particles in patients with proteinuria. Clin Chim Acta 414: 241–245, 2012 [DOI] [PubMed] [Google Scholar]
  • 46.Kounnas MZ, Haudenschild CC, Strickland DK, Argraves WS: Immunological localization of glycoprotein 330, low density lipoprotein receptor related protein and 39 kDa receptor associated protein in embryonic mouse tissues. In Vivo 8: 343–351, 1994 [PubMed] [Google Scholar]
  • 47.Basso F, Freeman L, Knapper CL, Remaley A, Stonik J, Neufeld EB, Tansey T, Amar MJ, Fruchart-Najib J, Duverger N, Santamarina-Fojo S, Brewer HB, Jr: Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res 44: 296–302, 2003 [DOI] [PubMed] [Google Scholar]
  • 48.Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS: Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115: 1333–1342, 2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Argraves KM, Gazzolo PJ, Groh EM, Wilkerson BA, Matsuura BS, Twal WO, Hammad SM, Argraves WS: High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem 283: 25074–25081, 2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Murphy AJ, Funt S, Gorman DJ, Tall AR, Wang N: Pegylation of HDL decreases plasma clearance and enhances anti-atherogenic activity. Circ Res 113: e1–9, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the American Society of Nephrology : JASN are provided here courtesy of American Society of Nephrology

RESOURCES